Author:
Embi Peter J.,Levy Matthew E.,Naleway Allison L.,Patel Palak,Gaglani Manjusha,Natarajan Karthik,Dascomb Kristin,Ong Toan C.,Klein Nicola P.,Liao I-Chia,Grannis Shaun J.,Han Jungmi,Stenehjem Edward,Dunne Margaret M.,Lewis Ned,Irving Stephanie A.,Rao Suchitra,McEvoy Charlene,Bozio Catherine H.,Murthy Kempapura,Dixon Brian E.,Grisel Nancy,Yang Duck-Hye,Goddard Kristin,Kharbanda Anupam B.,Reynolds Sue,Raiyani Chandni,Fadel William F.,Arndorfer Julie,Rowley Elizabeth A.,Fireman Bruce,Ferdinands Jill,Valvi Nimish R.,Ball Sarah W.,Zerbo Ousseny,Griggs Eric P.,Mitchell Patrick K.,Porter Rachael M.,Kiduko Salome A.,Blanton Lenee,Zhuang Yan,Steffens Andrea,Reese Sarah E.,Olson Natalie,Williams Jeremiah,Dickerson Monica,McMorrow Meredith,Schrag Stephanie J.,Verani Jennifer R.,Fry Alicia M.,Azziz-Baumgartner Eduardo,Barron Michelle A.,Thompson Mark G.,DeSilva Malini B.
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health(social science),Epidemiology
Reference10 articles.
1. Prevalence of immunosuppression among US adults, 2013.;Harpaz;JAMA,2016
2. Factors associated with COVID-19-related death using OpenSAFELY.;Williamson;Nature,2020
3. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study.;Deepak;Ann Intern Med,2021.
4. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States.;Tenforde;Clin Infect Dis,2021
5. CDC. COVID-19: Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html